Papillomavirus Research最新文献

{"title":"Anemia and neutrophil-to-lymphocyte ratio are prognostic in p16-positive oropharyngeal carcinoma treated with concurrent chemoradiation","authors":"Philippe Gorphe ,&nbsp;Younès Chekkoury Idrissi ,&nbsp;Yungan Tao ,&nbsp;Antoine Schernberg ,&nbsp;Dan Ou ,&nbsp;Stéphane Temam ,&nbsp;Odile Casiraghi ,&nbsp;Pierre Blanchard ,&nbsp;Haïtham Mirghani","doi":"10.1016/j.pvr.2017.12.002","DOIUrl":"10.1016/j.pvr.2017.12.002","url":null,"abstract":"<div><h3>Objectives</h3><p>We investigated the prognostic value of pre-treatment hematological parameters in patients with p16-positive oropharyngeal squamous-cell carcinoma (OPSCC).</p></div><div><h3>Material and methods</h3><p>Neutrophil count, lymphocyte count, neutrophil-to-lymphocyte ratio (NLR), and hemoglobin concentration measurement (Hb), were collected on day one of treatment. Endpoints were overall survival (OS) and progression-free survival (PFS). All patients were planned to receive concurrent chemoradiation. Staging were reviewed according to the recent AJCC 8th edition.</p></div><div><h3>Results</h3><p>We included 167 patients in this study. In multivariate analyses, a smoking history &gt; 30 packyears was associated with decreased OS (p = 0.009; HR, 3.4827) and PFS (p = 0.042; HR, 2.421); Hb &lt; 12<!--> <!-->g/dL was associated with impaired OS (p = 0.007; HR, 6.527) and PFS (p = 0.014; HR, 4.092); an NLR &gt; 5 before treatment was associated with decreased OS (p = 0.042; HR, 2.945). Hemoglobin concentration and the NLR were not correlated (p = 0.577), nor anemia and an NLR &gt; 5 (p = 0.167). Patients with an NLR &gt; 5 had a significantly higher rate of disease recurrence (30.8% vs. 8.4%, p = 0.0299, RR = 3.922, 95% CI 1.351–11.386).</p></div><div><h3>Discussion</h3><p>We found hemoglobin level and the NLR to be independent prognostic factors in p16-positive OPSCC patients. This approach is to be considered for further clinical investigations, and its significance in treatment decision-making should be further explored.</p></div>","PeriodicalId":46835,"journal":{"name":"Papillomavirus Research","volume":"5 ","pages":"Pages 32-37"},"PeriodicalIF":3.2,"publicationDate":"2018-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pvr.2017.12.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35667619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pooled analysis of HPV infection in paired anal and cervical samples, by HIV status","authors":"Gary Clifford IARC HPV study group.","doi":"10.1016/j.pvr.2018.07.006","DOIUrl":"10.1016/j.pvr.2018.07.006","url":null,"abstract":"<div><h3>Background</h3><p>In light of HPV16's unique carcinogenicity in the anus, knowledge of anal HPV16 prevalence may be a useful surrogate for stratifying groups of women at differing anal cancer risk based on routinely available cervical cancer screening outcomes.</p></div><div><h3>Methods</h3><p>47 relevant studies including 12,000+ samples were identified in PubMed up to March, 2018, Collaborators were invited to share individual-level data on at least age, and type-specific HPV infection in paired cervical and anal samples, by HIV status.</p></div><div><h3>Results</h3><p>The pooled dataset currently includes 4,729 HIV-negative and 968 HIV-positive women. Among HIV-negative women, anal HPV16 prevalence increased from 1% in 3,118 cervical HR-HPV-negative to 10% in 848 h-HPV-positive women (PR=7.4,5.1–10.5), and from 2% in 3,998 cervical HPV16-negative to 30% in 273 cervical HPV16-positive women (PR=14.8,11.2–19.7). Among HIV-positive women, anal HPV16 increased from 7% in 451 cervical HR-HPV-negative to 19% in 408 cervical HR-HPV-positive women (PR=2.8,1.9–4.2), and from 9% in 750 cervical HPV16-negative to 38% in 109 cervical HPV16-positive women (PR=4.3,3.1–6.0). Anal HPV16 also increased with severity of cervical cytopathology, but the association was not significant after adjustment for cervical HPV status, irrespective of HIV status. In all strata of cervical outcomes, anal HPV16 infection was higher in HIV-positive than HIV-negative women, most often significantly so.</p></div><div><h3>Conclusions</h3><p>Cervical abnormalities predict anal HPV16 prevalence, but do not offer additional discriminatory power over cervical HPV status. Cervical HPV16-positive women, whether HIV-positive (38%) or HIV-negative (30%), show similar anal HPV16 prevalence as meta-analyses of HIV-positive MSM (~35%), the population with highest known anal cancer risk.</p></div>","PeriodicalId":46835,"journal":{"name":"Papillomavirus Research","volume":"5 ","pages":"Pages S2-S3"},"PeriodicalIF":3.2,"publicationDate":"2018-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pvr.2018.07.006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42463416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Awareness and knowledge of anal cancer in a community-recruited sample targeting people with HIV and gay/bisexual men","authors":"Richard Hillman ,&nbsp;Lance Feeney ,&nbsp;Jeff Jin ,&nbsp;Craig Cooper ,&nbsp;David Templeton ,&nbsp;Matt O’Dwyer ,&nbsp;Mary Poynten","doi":"10.1016/j.pvr.2018.07.013","DOIUrl":"10.1016/j.pvr.2018.07.013","url":null,"abstract":"<div><h3>Background</h3><p>Anal cancer disproportionately affects gay and bisexual men (GBM), especially those with HIV infection. We explored the awareness and understanding of human papillomavirus (HPV) and anal cancer in a community-based cohort, to inform future evidence-based public health interventions.</p></div><div><h3>Methods</h3><p>Participants recruited through advertisements at gay and HIV community organisations completed an anonymous online questionnaire that assessed knowledge, understanding and experience of anal HPV, HPV vaccination, anal cancer screening and perceived personal risk of anal cancer.</p></div><div><h3>Results</h3><p>Of 1660 questionnaires returned, 1535 (92.5%) were from GBM, of whom the majority thought their risk of anal cancer was the same, or lower, than that of the general population. 196 (13.5%) participants reported ever having talked to their doctor about anal HPV and/or anal cancer. The discussion was initiated by the patient in more than half (58.7%) of cases, but was more likely to be doctor-initiated by participants who were HIV positive than negative/unknown (51.6% vs 35.7%, p=0.037). Only a small minority (12.7%) had talked to their doctor about anal HPV and/or anal cancer and (11.8%) had an anal cancer examination. Less than one third (32.3%) had heard of HPV vaccination and only 3.0% of men aged ≤ 26 years had received HPV vaccination.</p></div><div><h3>Conclusions</h3><p>Knowledge and awareness of anal cancer was generally very poor in GBM, who are at elevated risk of anal cancer. Specific information targeted at this group could potentially raise awareness, leading to earlier diagnosis and improved outcomes. Young GBM need education around the importance of HPV vaccination.</p></div>","PeriodicalId":46835,"journal":{"name":"Papillomavirus Research","volume":"5 ","pages":"Page S5"},"PeriodicalIF":3.2,"publicationDate":"2018-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pvr.2018.07.013","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44111448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The prevalence of positive anorectal gonorrhea and Chlamydia NAAT testing on routine screening for all high resolution anoscopy performed at a community health center","authors":"James Braun DO,&nbsp;William DeWitt MD,&nbsp;Meera Shah MD,&nbsp;Eddie Meraz NP,&nbsp;Chance Krempasky NP,&nbsp;Rudy Guadron NP,&nbsp;Asa Radix MD","doi":"10.1016/j.pvr.2018.07.005","DOIUrl":"10.1016/j.pvr.2018.07.005","url":null,"abstract":"<div><h3>Background</h3><p>Our community-based clinic decided to implement routine screening for anorectal Gonorrhea (GC) and Chlamydia (CT) for patients undergoing HRA for anal cancer prevention, due to high risk for asymptomatic GC and CT among our patient population (predominantly HIV+ MSM in NYC) and the impact undiagnosed GC/CT infection may have on recovery after biopsy or ablation of HPV-related lesions. In 2016, the CDC reported a prevalence of anorectal GC and CT of 0.146% and 0.497% in the general population nationally, and 12.1% and 12.7% in MSM in NYC clinics in the STD Surveillance Network.</p></div><div><h3>Methods</h3><p>Retrospective chart review for all HRA completed in 2017 using associated CPT and testing codes.</p></div><div><h3>Results</h3><p>839 HRA procedures were done in 2017. Of the anorectal NAATs performed, 6.6% were positive for either GC and/or CT (4% for GC and 3% for CT).</p></div><div><h3>Conclusions</h3><p>Implementing routine screening for anorectal GC/CT at every HRA for HPV-related disease revealed a prevalence of concurrent anorectal GC and/or CT infection well above national prevalence for the general population, though at a lower rate than anorectal GC/CT among MSM seeking screening or treatment in NYC DOH clinics. We were unable to make conclusions about how treating these incidental infections impacted recovery after the procedure, as this was outside the scope of this limited chart review. But the prevalence of GC/CT infection discovered in this analysis supports the importance of adding routine GC/CT screening for all patients undergoing HRA for the diagnosis or treatment of HPV-related anal neoplasia.</p></div>","PeriodicalId":46835,"journal":{"name":"Papillomavirus Research","volume":"5 ","pages":"Page S2"},"PeriodicalIF":3.2,"publicationDate":"2018-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pvr.2018.07.005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41612893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Screening for anal dysplasia in women with a history of human papillomavirus related lower genital tract pathology","authors":"K. Leber ,&nbsp;M. van Beurden ,&nbsp;H.J. Zijlmans ,&nbsp;L. Dewit ,&nbsp;O. Richel ,&nbsp;M. van Broekhuizen ,&nbsp;S.M.E. Vrouenraets","doi":"10.1016/j.pvr.2018.07.018","DOIUrl":"10.1016/j.pvr.2018.07.018","url":null,"abstract":"<div><h3>Background</h3><p>Women with a human papillomavirus related history of cervical, vaginal or vulvar high-grade dysplasia or cancer are at increased risk to develop anal dysplasia or anal cancer. Screening for anal cancer precursors (squamous intraepithelial lesions (SIL)) with high resolution anoscopy (HRA) in high-risk populations is subject of debate. In this study we evaluated standardized intra-anal SIL screening using HRA in high-risk female patients.</p></div><div><h3>Methods</h3><p>A retrospective observational study was performed to evaluate the prevalence of intra-anal SIL in women with a history of vulvar high-grade SIL (HSIL) and perianal HSIL diagnosed at the Netherlands Cancer Institute, who were referred for intra-anal SIL screening using HRA in the MC Slotervaart between 2015 and 2017.</p></div><div><h3>Results</h3><p>22 female patients were screened for anal SIL using HRA. 19 females had a history of biopsy proven vulvar HSIL and 19 females had a history of biopsy proven perianal HSIL. Eleven (50%) patients had a history of multizonal HSIL at three or more perianogenital locations. No anal cancer was found at screening, 7 (32%) patients were diagnosed with anal HSIL and 7 (32%) patients with low-grade anal SIL.</p></div><div><h3>Conclusions</h3><p>We found a high prevalence of anal HSIL in women with HPV related lower genital tract dysplasia. Intra-anal SIL screening using HRA in this high risk population seems to be justified. However, HRA is an invasive screening method. Studying other, less invasive screening methods remains important.</p></div>","PeriodicalId":46835,"journal":{"name":"Papillomavirus Research","volume":"5 ","pages":"Page S7"},"PeriodicalIF":3.2,"publicationDate":"2018-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pvr.2018.07.018","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45366810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patterns of repeated anal cytology results among HIV-positive and HIV-negative men who have sex with men","authors":"Hilary A. Robbins ,&nbsp;Dorothy J. Wiley ,&nbsp;Ken Ho ,&nbsp;Michael Plankey ,&nbsp;Susheel Reddy ,&nbsp;Nancy Joste ,&nbsp;Teresa M. Darragh ,&nbsp;Elizabeth C. Breen ,&nbsp;Stephen Young ,&nbsp;Gypsyamber D’Souza","doi":"10.1016/j.pvr.2018.04.001","DOIUrl":"10.1016/j.pvr.2018.04.001","url":null,"abstract":"<div><h3>Background</h3><p>Men who have sex with men (MSM) are at increased risk for anal cancer. In cervical cancer screening, patterns of repeated cytology results are used to identify low- and high-risk women, but little is known about these patterns for anal cytology among MSM.</p></div><div><h3>Methods</h3><p>We analyzed Multicenter AIDS Cohort Study (MACS) data for MSM who were offered anal cytology testing annually (HIV-positive) or every 2 years (HIV-negative) for 4 years.</p></div><div><h3>Results</h3><p>Following an initial negative (normal) cytology, the frequency of a second negative cytology was lower among HIV-positive MSM with CD4 ≥ 500 (74%) or CD4 &lt; 500 (68%) than HIV-negative MSM (83%) (p &lt; 0.001). After an initial abnormal cytology, the frequency of a second abnormal cytology was highest among HIV-positive MSM with CD4 &lt; 500 (70%) compared to CD4 ≥ 500 (53%) or HIV-negative MSM (46%) (p = 0.003). Among HIV-positive MSM with at least three results, 37% had 3 consecutive negative results; 3 consecutive abnormal results were more frequent among CD4 &lt; 500 (22%) than CD4 ≥ 500 (10%) (p = 0.008).</p></div><div><h3>Conclusions</h3><p>More than one-third of HIV-positive MSM have consistently negative anal cytology over three years. Following abnormal anal cytology, a repeated cytology is commonly negative in HIV-negative or immunocompetent HIV-positive men, while persistent cytological abnormality is more likely among HIV-positive men with CD4 &lt; 500.</p></div>","PeriodicalId":46835,"journal":{"name":"Papillomavirus Research","volume":"5 ","pages":"Pages 143-149"},"PeriodicalIF":3.2,"publicationDate":"2018-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pvr.2018.04.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35983808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter-to-the-Editor in response to “Tanton C, et al. Human papillomavirus (HPV) in young women in Britain: Population-based evidence ofthe effectiveness of the bivalent immunisation programme and burden of quadrivalent and 9-valent vaccine types. Papillomavirus Res. 2017 Jun;3:36-41.doi: 10.1016/j.pvr.2017.01.001.”","authors":"Martin Ryser,&nbsp;Adrienne Guignard,&nbsp;Valérie Berlaimont","doi":"10.1016/j.pvr.2017.12.005","DOIUrl":"10.1016/j.pvr.2017.12.005","url":null,"abstract":"","PeriodicalId":46835,"journal":{"name":"Papillomavirus Research","volume":"5 ","pages":"Pages 61-62"},"PeriodicalIF":3.2,"publicationDate":"2018-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pvr.2017.12.005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35685764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Murine HPV16 E7-expressing transgenic skin effectively emulates the cellular and molecular features of human high-grade squamous intraepithelial lesions","authors":"Z.K. Tuong,&nbsp;K. Noske,&nbsp;P. Kuo,&nbsp;A.A. Bashaw,&nbsp;S.M. Teoh,&nbsp;I.H. Frazer","doi":"10.1016/j.pvr.2017.10.001","DOIUrl":"10.1016/j.pvr.2017.10.001","url":null,"abstract":"<div><p>Currently available vaccines prevent HPV infection and development of HPV-associated malignancies, but do not cure existing HPV infections and dysplastic lesions. Persistence of infection(s) in immunocompetent patients may reflect induction of local immunosuppressive mechanisms by HPV, providing a target for therapeutic intervention. We have proposed that a mouse, expressing HPV16 E7 oncoprotein under a Keratin 14 promoter (K14E7 mice), and which develops epithelial hyperplasia, may assist with understanding local immune suppression mechanisms that support persistence of HPV oncogene-induced epithelial hyperplasia. K14E7 skin grafts recruit immune cells from immunocompetent hosts, but consistently fail to be rejected. Here, we review the literature on HPV-associated local immunoregulation, and compare the findings with published observations on the K14E7 transgenic murine model, including comparison of the transcriptome of human HPV-infected pre-malignancies with that of murine K14E7 transgenic skin. We argue from the similarity of i) the literature findings and ii) the transcriptome profiles that murine K14E7 transgenic skin recapitulates the cellular and secreted protein profiles of high-grade HPV-associated lesions in human subjects. We propose that the K14E7 mouse may be an appropriate model to further study the immunoregulatory effects of HPV E7 expression, and can facilitate development and testing of therapeutic vaccines.</p></div>","PeriodicalId":46835,"journal":{"name":"Papillomavirus Research","volume":"5 ","pages":"Pages 6-20"},"PeriodicalIF":3.2,"publicationDate":"2018-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pvr.2017.10.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36137642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Electrocautery ablation of anal HSIL: correlation of treatment outcomes with histological features and HPV genotypes","authors":"Yuxin Liu M.D. Ph.D. ,&nbsp;Keith Sigel M.D. Ph.D ,&nbsp;Michael M. Gaisa M.D. Ph.D.","doi":"10.1016/j.pvr.2018.07.020","DOIUrl":"10.1016/j.pvr.2018.07.020","url":null,"abstract":"<div><h3>Background</h3><p>Electrocautery ablation (EA) is a widely used treatment modality for HPV-induced anal high-grade squamous intraepithelial lesions (HSIL). Roughly half of the targeted HSILs persist or recur following ablation. Several clinical characteristics have been linked to EA resistance; however, there is little data on whether and how ablation outcomes are affected by lesional histology and HPV genotypes.</p></div><div><h3>Methods</h3><p>Among lesions that responded to EA and those that recurred, we compared mitotic activity, type of dysplasia (classic vs. keratinized) and degree of dysplasia (AIN2 vs. AIN3). HPV genotypes were tested using cytology samples.</p></div><div><h3>Results</h3><p>97 HIV-infected patients with HSIL underwent EA and surveillance. Upon follow-up (median 10 months, range 5–37), 44 (45%) patients revealed benign or LSIL at the prior ablation site (EA-sensitive group), whereas 53 (55%) revealed HSIL (EA-resistant group). Age, gender, and race distribution were similar regardless of ablation outcomes. The EA-sensitive group tended to have solitary lesions (60%), non-16/18 h-HPV infection (68%), and HPV clearance (18%), whereas the EA-resistant group had multiple synchronous lesions (81%) and HPV16/18 infection (57%). Compared to EA-sensitive lesions, resistant ones were characterized by higher mitotic activity (mean 7 vs. 3/HPF), a higher percentage of AIN3 (70% vs. 36%), as well as the keratinized dysplasia (74% vs. 48%).</p></div><div><h3>Conclusions</h3><p>Anal HSIL ablation resistance is associated with multiple synchronous lesions, HPV16/18 infection, high mitotic activity, AIN3, and keratinized dysplasia. Patients with these types of lesions are at high risk of recurrence and warrant careful surveillance.</p></div>","PeriodicalId":46835,"journal":{"name":"Papillomavirus Research","volume":"5 ","pages":"Page S8"},"PeriodicalIF":3.2,"publicationDate":"2018-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pvr.2018.07.020","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43589323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum testosterone and estradiol modify risk of anal HPV16/18 infections but only estradiol influences risk for histological high-grade squamous intraepithelial lesions (HSIL)","authors":"Dorothy J. Wiley PhD ,&nbsp;Hilary K. Hsu ,&nbsp;Ravi Jasuja ,&nbsp;Todd T. Brown ,&nbsp;Brian Lawney ,&nbsp;Rong Guo ,&nbsp;David Elashoff ,&nbsp;Stephen Young ,&nbsp;Nancy Joste ,&nbsp;Shalender Bhasin ,&nbsp;Steven Whitford ,&nbsp;Ross Cranston ,&nbsp;Matt Moran ,&nbsp;Ernesto Rodriguez ,&nbsp;Gypsyamber D'Souza ,&nbsp;Susheel Reddy","doi":"10.1016/j.pvr.2018.07.035","DOIUrl":"10.1016/j.pvr.2018.07.035","url":null,"abstract":"<div><h3>Background</h3><p>We reported higher serum free testosterone (FT) and increased anal-HPV16/18 infection prevalence in MSM. Associations between serum-FT and -estradiol and anal-HPV16/18 infections and histological HSIL (hHSIL) are unclear.</p></div><div><h3>Methods</h3><p>Two cross-sectional analyses were performed. 340 HIV-infected/HIV-uninfected Multicenter AIDS Cohort MSM were tested for anal HPVs; another 214 men were evaluated using HRA/biopsy with multiple assessments for some totaling 336 HRAs. Serum specimens collection preceded HPV and HRA visits by 24(<u>+</u>9) months and were tested for albumin, SHBG (radioimmunoassay), and total testosterone and estradiol (TE2) (LC/MS); serum-FT (pg/mL) was estimated. Anal swabs were tested for 37 HPVs (PCR) and classified: HPV16/18+, other Group-1 and -2 high-risk HPVs+ (hrHPVs); low-risk HPVs+ (lrHPVs), vs. none. Biopsies were evaluated as hHSIL vs. &lt;hHSIL. Multivariable-adjusted GEE logistic regression models assessed relationships between log_e-transform_ed FT and TE2, and HPV16/18+ and hHSIL, separately. Sociodemographic/behavioral covariates were included.</p></div><div><h3>Results</h3><p>Adjusted estimates showed higher FT increased odds of HPV16/18-infection (OR=1.9 (1.2–2.9)), but odds were inversely associated with TE2 (OR=0.68 (0.49–0.94)). White race and other Group-1-hrHPVs+ increased odds for HPV16/18 infection (OR=2.6 (1.2–5.9) and (OR=1.7 (1.1–2.5)), but neither HIV-infection/CD4+count, receptive anal intercourse partnerships; exogenous-testosterone nor tobacco use increased HPV16/18-infection odds. Serum-FT was not associated with odds of hHSIL (OR=1.1 (0.7, 1.8)), but serum-TE2 and hHSIL was: OR=0.5 (0.3, 0.9). Men testing HPV16/18+ alone showed higher odds of hHSIL than hrHPV-negative men (OR=4.3 (1.7, 10.7)).</p></div><div><h3>Conclusions</h3><p>Higher serum-FT increased odds of anal HPV16/18-infection but not hHSIL. Consistent across both analyses, and unexpectely, higher serum-TE2 lowered odds of both HPV16/18+ and hHSIL in these MSM.</p></div>","PeriodicalId":46835,"journal":{"name":"Papillomavirus Research","volume":"5 ","pages":"Page S14"},"PeriodicalIF":3.2,"publicationDate":"2018-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pvr.2018.07.035","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48604207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}